Phase IIa safety and efficacy of milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients.

被引：0
|
作者：
Villa, Erica
Piscaglia, Fabio
Geva, Rabit
Dalecos, George
Papatheodoridis, George
Ciomei, Marina
Davite, Christina
Crivori, Patrizia
Palejwala, Vaseem
Jacob, Jules
Hamzeh, Fayez
Shailubhai, Kunwar
Santoro, Armando
Sangiovanni, Angelo
机构：
[1] Policlin Modena, Modena, Italy
[2] Univ Bologna, Bologna, Italy
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[4] Gen Univ Hosp Larissa, Thessaly, Greece
[5] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp Athens, Athens, Greece
[6] Nerviano Med Sci, Nerviano, Italy
[7] NMS Grp, Clin Org Strategies & Solut CLIOSS, Nerviano, Italy
[8] Tiziana Life Sci, Doylestown, PA USA
[9] Tlziana LifeSceinces, Doylestown, PA USA
[10] Humanitas Univ, Pieve Emanuele, Italy
[11] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16711
引用
收藏
页数：2
相关论文
共 12 条
  • [1] Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients.
    Besse, Benjamin
    Garassino, Marina Chiara
    Rajan, Arun
    Novello, Silvia
    Mazieres, Julien
    Weiss, Glen J.
    Kocs, Darren M.
    Barnett, John Mark
    Davite, Cristina
    Crivori, Patrizia
    Giaccone, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.
    Bitzer, Michael
    Horger, Marius
    Ganten, Tom M.
    Lauer, Ulrich M.
    Woerns, Marcus A.
    Siveke, Jens T.
    Dollinger, Matthias M.
    Gerken, Guido
    Wege, Henning
    Giannini, Edoardo G.
    Zagonel, Vittorina
    Cillo, Umberto
    Trevisani, Franco
    Santoro, Armando
    Montesarchio, Vincenzo
    Hauns, Bernhard
    Asche, Julia
    Jankowsky, Ruediger
    Mais, Anna
    Hentsch, Bernd
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
    Lim, Ho Yeong
    Heo, Jeong
    Choi, Hye Jin
    Lin, Cheng-Yao
    Yoon, Jung-Hwan
    Hsu, Chiun
    Rau, Kun-Ming
    Poon, Ronnie T. P.
    Yeo, Winnie
    Park, Joong-Won
    Tay, Miah Hiang
    Hsieh, Wen-Son
    Kappeler, Christian
    Rajagopalan, Prabhu
    Krissel, Heiko
    Jeffers, Michael
    Yen, Chia-Jui
    Tak, Won Young
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5976 - 5985
  • [4] Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)
    Decaens, T.
    Barone, C.
    Assenat, E.
    Wermke, M.
    Fasolo, A.
    Merle, P.
    Blanc, J. F.
    Grando, V.
    Bruns, R.
    Straub, J.
    Zhao, C.
    Faivre, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 235 - 235
  • [5] Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.
    Martell, Robert E.
    Puzanov, Igor
    Ma, Wen Wee
    Santoro, Armando
    Dy, Grace K.
    Goff, Laura Williams
    Fetterly, Gerald J.
    Michael, Shaunita A.
    Means-Powell, Julie Ann
    Chai, Feng
    Lamar, Maria
    Simonelli, Matteo
    Chiang, Wendy M.
    Jarboe, Jamie
    Schwartz, Brian E.
    Adjei, Alex A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study
    Gao, Ya
    Lu, Haohao
    Xiong, Zhifan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Cassaday, Ryan D.
    Goy, Andre
    Advani, Suresh
    Chawla, Purvi
    Nachankar, Rajesh
    Gandhi, Mansi
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (07): : 392 - 397
  • [8] The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study
    Guo, Zheng
    Zhu, Huabin
    Zhang, Xiufang
    Huang, Li
    Wang, Xiangcai
    Shi, Huaqiu
    Yu, Li
    Qiu, Yingwei
    Tu, Fuping
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study
    Kudo, Masatoshi
    Finn, Richard S. S.
    Galle, Peter R. R.
    Zhu, Andrew X. X.
    Ducreux, Michel
    Cheng, Ann-Lii
    Ikeda, Masafumi
    Tsuchiya, Kaoru
    Aoki, Ken-ichi
    Jia, Jing
    Lencioni, Riccardo
    LIVER CANCER, 2023, 12 (03) : 238 - 250
  • [10] SAFETY, PHARMACOKINETICS (PK) AND EFFICACY OF CYCLIN-DEPENDENT KINASE (CDK) 4 AND 6 INHIBITOR, PALBOCICLIB (PD-0332991): RESULTS FROM A PHASE 1 STUDY IN JAPANESE PATIENTS (PTS)
    Mukai, H.
    Yoshino, T.
    Osera, S.
    Sasaki, M.
    Shimizu, C.
    Yonemori, K.
    Koudaira, M.
    Tanabe, Y.
    Matsuda, N.
    Mizutani, N.
    Mori, Y.
    Hashigaki, S.
    Nagasawa, T.
    Umeyama, Y.
    Randolph, S.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2014, 25
12